e-Therapeutics plc Board Changes (5843Q)
01 Marzo 2021 - 1:00AM
UK Regulatory
TIDMETX
RNS Number : 5843Q
e-Therapeutics plc
01 March 2021
e-therapeutics plc
("e-therapeutics" or the "Company")
Board Changes
Oxford, UK, 1 March 2021 - e-therapeutics plc (AIM: ETX) today
announces the following changes to its Board of Directors. With
immediate effect, the role of Executive Chairman and Chief
Executive will be split so that Professor Trevor Jones, an
Independent Non-Executive Director of the Company since 2015, will
assume the role of Independent Non-Executive Chairman and Ali
Mortazavi will continue in his role as Chief Executive Officer.
Trevor has over 40 years' experience in the pharmaceutical and
biotechnology industries as well as in academia. He has held
significant roles including Director of Allergan Inc. from 2005 to
2015 and R&D Director of The Wellcome Foundation from 1987 to
1994, where he was responsible for the development of AZT, Zovirax,
Lamictal and Malarone. He is Visiting Professor at King's College,
London and holds honorary degrees and Gold Medals from seven
universities.
The Company continues to search for an additional Non-Executive
Director to further strengthen the Board.
Professor Trevor Jones, Non-Executive Chairman of
e-therapeutics, commented: "I am delighted with my appointment.
e-therapeutics has a world-class team of scientists who are
discovering entirely novel therapeutics using their unique approach
to network pharmacology. The appointment last year of Ali Mortazavi
has led to a step-change in the Company's performance and we are in
a strong position to continue our successful internal programmes
and partnerships with major pharmaceutical and biotech
companies."
Ali Mortazavi, Chief Executive Officer of e-therapeutics,
commented: "I am very pleased that Trevor has agreed to become the
Non-Executive Chairman of e-therapeutics. Having served as a
Non-Executive Director for many years, Trevor has an in-depth
knowledge of the Company and I am very much looking forward to
working more closely with him.
"Trevor has had a distinguished career at the helm of leading
pharmaceutical and governmental organisations during which he has
made major contributions to human health and to business. His
breadth of experience in all aspects of the biopharma industry will
be invaluable to us as we strive to achieve our long-term ambitions
in drug development."
Enquiries:
e-therapeutics plc
Ali Mortazavi, CEO Tel: +44 (0)1993 883
125
www.etherapeutics.co.uk
SP Angel Corporate Finance LLP Tel: +44(0)20 3470
0470
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate
Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)
About e-therapeutics plc
e-therapeutics plc is an Oxford, UK-based company with a
powerful computer-based approach to drug discovery, founded on its
industry-leading expertise in network biology to fully capture
disease complexity. The Company combines network science, machine
learning, artificial intelligence, statistics and big data with
expertise in drug discovery and development to transform the search
for new medicines and intervention strategies.
e-therapeutics has developed an in silico laboratory that
enables the rapid screening of millions of compounds and the
identification of small sub-sets that are enriched for highly
active hits. Its proprietary platform also has novel applications
in functional genomics, being able to analyse complex genetic
datasets, provide a deep understanding of pathological mechanisms
and distil actionable insights for the discovery of novel drugs,
biomarkers and diagnostics.
e-therapeutics has deployed and validated its disease-agnostic
drug discovery platform both in house and with partners, including
Novo Nordisk, Galapagos NV and a US-based, top 5 pharmaceutical
company.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOADKABBOBKDDBB
(END) Dow Jones Newswires
March 01, 2021 02:00 ET (07:00 GMT)
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
E-therapeutics (LSE:ETX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024